Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback